Market Cap : 75.53 B | Enterprise Value : 67.13 B | PE Ratio : 23.81 | PB Ratio : 6.32 |
---|
NAS:VRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vertex Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2022 was 10.92.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vertex Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.
The historical rank and industry rank for Vertex Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Vertex Pharmaceuticals's highest Cash to Debt Ratio was 26.61. The lowest was 0.66. And the median was 2.91.
VRTX's Cash-to-Debt is ranked worse thanThe historical data trend for Vertex Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Vertex Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 7524.9 | / | (46.9 | + | 887.2) | |
= | 8.06 |
Vertex Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 9253.4 | / | (0 | + | 847.3) | |
= | 10.92 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Upadhyay Suketu | director | 345 E. MAIN STREET WARSAW IN 46580 |
Garber Alan M | director | 3355 MILTON COURT MOUNTAIN VIEW CA 94040 |
Kearney Terrence C | director | IN CARE OF HOSPIRA, INC. 275 NORTH FIELD DRIVE LAKE FOREST IL 60045 |
Carney Lloyd | director | C/O MICROMUSE INC 139 TOWNSEND ST SAN FRANCISCO CA 94107 |
Mckenzie Diana | director | METLIFE 200 PARK AVENUE NEW YORK NY 10166 |
Bhatia Sangeeta N. | director | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Lee Yuchun | director | 170 TRACER LA. WALTHAM MA 02451 |
Ambrose Kristen | officer: SVP & Chief Accounting Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 |
Mcglynn Margaret G | director | C/O MERCK & CO INC ONE MERCK DRIVE PO BOX 100 WHITEHOUSE STATION NJ 08889-0100 |
Liu Joy | officer: SVP, General Counsel | C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 |
Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Bozic Carmen | officer: EVP and CMO | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Wagner Charles F Jr | officer: EVP & Chief Financial Officer | C/O MILLIPORE CORP BILLERICA MA 01820 |
Arbuckle Stuart A | officer: EVP, COO | VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139 |
Kewalramani Reshma | director, officer: CEO & President | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
From GuruFocus
Other Sources
By Zacks 2022-03-29
By Zacks 2022-04-06
By Zacks 2022-03-25
By Zacks 2022-03-28
By Zacks 2022-03-29
By Zacks 2022-03-25
By Zacks 2022-04-04
By Fool 2022-04-01
By Zacks 2022-03-24
By Zacks 2022-04-01
By Zacks 2022-03-28
By Zacks 2022-03-31
By Zacks 2022-03-28
By Zacks 2022-03-28
By Zacks 2022-03-31